Madrigal Sales Jump 71% as Rezdiffra Adoption Expands
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) reported a 71% increase in second-quarter revenue as adoption of its liver-disease drug Rezdiffra expanded, though higher commercial and research spending widened …
Madrigal Sales Jump 71% as Rezdiffra Adoption Expands Read More